Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

Zorifertinib Receives NMPA Approval for EGFR+ NSCLC With CNS Metastases

November 20th 2024

Zorifertinib has received NMPA approval in the first line for EGFR-mutant advanced or metastatic non–small cell lung cancer displaying CNS metastases.

MT-302 Utilizes Novel Mechanism of Action to Offer a Unique Treatment in Epithelial Tumors

November 19th 2024

Rasha Cosman, BSc, MBBS, FRACP, and Charlotte Lemech, MBBS, discuss the phase 1 MYE Symphony study (NCT05969041) of MT-302 in advanced or metastatic epithelial cancers.

NXP800 Demonstrates Single-Agent Activity in ARID1a+ Platinum-Resistant Ovarian Cancer

November 14th 2024

NXP800 generated antitumor activity as monotherapy in platinum-resistant ovarian cancer harboring ARID1a mutations.

Eftilagimod Alpha Plus Pembrolizumab/Chemo Generates Improved Survival Trends in Advanced NSCLC

November 14th 2024

Eftilagimod alpha plus pembrolizumb and chemotherapy generated favorable survival data in nonsquamous NSCLC.

Belantamab Mafodotin Plus Bortezomib/Dexamethasone Extends OS in R/R Myeloma

November 14th 2024

Belantamab mafodotin plus bortezomib and dexamethasone met the key secondary end point of OS in relapsed/refractory multiple myeloma in the DREAMM-7 study.

Zolbetuximab Plus Chemotherapy Offers Survival Benefits in Treatment-Naive HER2– Gastric/GEJ Cancer

November 12th 2024

Zolbetuximab plus chemotherapy extended PFS and OS in HER2–, locally advanced unresectable or metastatic, CLDN18.2+ gastric/GEJ adenocarcinoma.

Personalized Initiatives Empower Patients to Actively Participate in Cancer Research

November 11th 2024

Investigators who champion patient-partnered cancer research have experienced challenges to their effective implementation.

THIO Plus Cemiplimab Displays Efficacy in Checkpoint Inhibitor–Resistant NSCLC

November 8th 2024

THIO plus cemiplimab displayed durable activity in patients with advanced checkpoint inhibitor–resistant NSCLC.

Frontline Vibostolimab/Pembrolizumab Plus Chemo Meets Futility Threshold in ES-SCLC

November 8th 2024

Co-formulated vibostolimab and pembrolizumab plus chemotherapy failed to improve OS in the first line vs atezolizumab plus chemotherapy in ES-SCLC.

MAGEA4 Opens the Door for Engineered Cellular Therapies in Solid Tumors

November 7th 2024

Brian A. Van Tine, MD, PhD, and David S. Hong, MD, discuss the MAGEA4 pathway and the FDA approval of afami-cel in synovial sarcoma.

NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies

November 6th 2024

NICE issued a final guidance recommending reimbursement of avapritinib monotherapy in adult patients with ASM, SM-AHN, or mast cell leukemia.

MI Cancer Seek Receives FDA Approval as Companion Diagnostic for Targeted Therapy Across Tumor Types

November 6th 2024

MI Cancer Seek has been granted FDA approval as a companion diagnostic for patients with cancer who may benefit from targeted therapy.

FDA Grants Orphan Drug Designation to LBL-034 for Multiple Myeloma

November 6th 2024

The FDA has granted orphan drug designation to LBL-034 for the treatment of patients with multiple myeloma.

Gynecologic Cancer Paradigm Sees Huge Gains With FDA-Approved Regimens

November 5th 2024

Experts in gynecologic oncology highlight multiple practice-altering clinical trial updates presented at ESMO and beyond in ovarian, cervical, and endometrial cancers.

FDA Approval Sought for Avutometinib Plus Defactinib in Recurrent KRAS+ Low-Grade Serous Ovarian Cancer

November 1st 2024

A rolling NDA seeking the approval of avutometinib plus defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer has been submitted to the FDA.

ESSA Discontinues Phase 2 Study of Masofaniten Plus Enzalutamide in mCRPC

November 1st 2024

The phase 2 study of masofaniten plus enzalutamide in mCRPC naive to second-generation antiandrogen therapy has been discontinued.

Inavolisib Regimen Approval Opens the Door for Triplet Therapies in HR+, HER2– Breast Cancer

October 31st 2024

Hope Rugo, MD, FASCO, discusses the FDA approval of inavolisib, how it will be incorporated into care, and the patient population evaluated in INAVO120.

FDA Grants Regenerative Medicine Advanced Therapy Designation to ALLO-316 in CD70+ Advanced RCC

October 31st 2024

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

FDA Advises Against Use of BioZorb Markers in Breast Cancer and Other Indications

October 30th 2024

The FDA has announced that BioZorb Markers and BioZorb LP Markers should no longer be used.

FDA Receives NDA for 3-Month Version of Leuprolide Mesylate for Advanced Prostate Cancer

October 30th 2024

The FDA has received an NDA seeking the approval of a 3-month formulation of leuprolide mesylate for advanced prostate cancer.